凱萊英(002821.SZ):參股子公司天津有濟醫藥擬引入產業資本增資擴股
格隆匯 12 月 22日丨凱萊英(002821.SZ)公佈,公司參股子公司天津有濟醫藥科技發展有限公司(“天津有濟醫藥”或“標的公司”)通過增資擴股的方式引入產業資本,以充實資本實力,全面提升公司平台價值和業務實力,擴大經營規模,帶來產業與社會資源。
此次交易具體內容為:天津海河凱萊英生物醫藥產業創新投資基金(有限合夥)(“海河凱萊英基金”)以人民幣2250萬元作為增資價款,認繳天津有濟醫藥30.00%的股份。增資完成後,海河凱萊英基金將持有天津有濟醫藥30.00%的股權。
天津有濟醫藥專注於瞄準新藥的設計目標和註冊目標,為廣大製藥公司提供藥理、毒理、藥代動力學評價相關的個性化方案設計、方法開發、過程實施等一站式的藥物評價技術服務。其核心團隊具有30年的新藥評價研究經驗,是中國最具權威的藥代動力學研究團隊之一。
此次增資擴股引入產業資本有助於天津有濟醫藥完善其股權結構和治理結構,助力天津有濟醫藥核心管理團隊藉助產業資本進一步完善一站式藥物評價服務平台的構建,有利於進一步擴大經營規模和客户服務能力,持續提升與公司業務的協同性,實現客户資源共享及專業化服務的優勢資源互補,帶來產業資本與社會資源的共贏。此次引入產業資本增資完成後,標的公司持續健康發展將對公司經營發展產生積極影響,增強與公司主業的協同及客户引流效應,符合公司整體的發展目標及長期發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.